%0 Journal Article
%T Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
%A Aaron Galaznik
%A Augustina Ogbonnaya
%A Douglas V. Faller
%A Eileen Farrelly
%A Huai-Che Shih
%A Jill A. Bell
%A Marlo Blazer
%A Michael Eaddy
%A Robert J. Fram
%J Archive of "PharmacoEconomics Open".
%D 2019
%R 10.1007/s41669-018-0100-5
%X Sample attrition. aDue to exclusion of patients with capitated claims for the cost analysis, 149 patients of the 209 treated HR-MDS patients were available for cost of care analyses. 1LT first-line therapy, AML acute myeloid leukemia, HR-MDS higher-risk myelodysplastic syndrome, MDS myelodysplastic syndrome, SCT stem cell transplan
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533351/